Research programme: viral vaccines - Mymetics Corporation
Alternative Names: Chikungunya virus infections - Mymetics; Zika virus infection - MymeticsLatest Information Update: 24 Jun 2021
At a glance
- Originator Mymetics Corporation
- Class Viral vaccines; Zika virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Chikungunya virus infections; Zika virus infection
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for research development in Chikungunya-virus-infections in Netherlands
- 28 Jun 2020 No recent reports of development identified for research development in Zika-virus-infection in Netherlands
- 28 Jan 2016 Early research in Chikungunya virus infections in Netherlands (unspecified route)
Development Overview
Introduction
Mymetics Corporation was developing viral vaccines against Chikungunya and Zika virus infections. However, the development of the vaccines is discontinued due to other priorities.
Key Development Milestones
As of December 2020, Mymetics Corporation reported that Chikungunya vaccine candidate program has been stopped or is on hold. Mymetics had started the discovery phase of the project and assessed the overall CHIKV glycoprotein yields in scale up insect cell culture. The project has been delayed due to other priorities and the company has no current plan to restart the vaccine development [1] .
Drug Properties & Chemical Synopsis
- Formulation unspecified
- Class Viral vaccines, Zika virus vaccines
- Mechanism of Action Immunostimulants
-
WHO ATC code
J07B (Viral Vaccines)
J07B-X (Other viral vaccines)
-
EPhMRA code
J7E (Viral Vaccines)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| Chikungunya virus infections | - | - | Discontinued (Preclinical) | Netherlands | unspecified / unspecified | Mymetics Corporation | 31 Dec 2020 |
| Zika virus infection | - | - | Discontinued (Research) | Netherlands | unspecified / unspecified | Mymetics Corporation | 31 Dec 2020 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| Mymetics Corporation | Originator | USA |
| Mymetics Corporation | Owner | USA |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 31 Dec 2020 | Phase Change - Discontinued | Discontinued for Zika virus infection in Netherlands (unspecified route) [1] Updated 24 Jun 2021 |
| 31 Dec 2020 | Phase Change - Discontinued | Discontinued for Chikungunya virus infections in Netherlands (unspecified route) [1] Updated 24 Jun 2021 |
| 31 Dec 2020 | Phase Change - Preclinical | Preclinical trials in Chikungunya virus infections in Netherlands (unspecified route), before December 2020 [1] Updated 24 Jun 2021 |
| 28 Jun 2020 | Phase Change - No development reported | No recent reports of development identified for research development in Chikungunya-virus-infections in Netherlands Updated 28 Jun 2020 |
| 28 Jun 2020 | Phase Change - No development reported | No recent reports of development identified for research development in Zika-virus-infection in Netherlands Updated 28 Jun 2020 |
| 28 Jan 2016 | Phase Change | Early research in Chikungunya virus infections in Netherlands (unspecified route) Updated 08 Feb 2016 |
| 28 Jan 2016 | Phase Change | Early research in Zika virus infection in Netherlands (unspecified route) Updated 08 Feb 2016 |
References
-
Mymetics Corporation SEC filing form 10 K December 2020. Internet-Doc 2021;.
Available from: URL: https://www.sec.gov/Archives/edgar/data/927761/000165495421003626/mymx_10k.htm
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG